Anemia after kidney transplantation; Its prevalence, risk factors, and independent association with graft and patient survival

A time-varying analysis

Heather Jones, Manish Talwar, Joseph M. Nogueira, Richard Ugarte, Charles Cangro, Hassaan Rasheed, David K. Klassen, Matthew R. Weir, Abdolreza Haririan

Research output: Contribution to journalArticle

Abstract

Introduction: Posttransplant anemia and its association with transplant outcomes have not been properly studied. Methods: We examined 530 renal allograft recipients transplanted at our center and followed up for 31.0±14.1 months. Hemoglobin (Hb), serum bicarbonate, and creatinine; use of erythropoiesis-stimulating agent (ESA) and iron; and immunosuppressive regimen data were obtained at multiple time points during 24-month posttransplant. Results: The overall prevalence of anemia was 89.4% at the time of transplant, dropping to 49.2% at 1 year and 44.3% at 2 years. ESA use decreased from 25.6% at 1 month to 8.23% at 24 months, only in 30.9% to 51.2% with severe anemia; 21.0% to 29.2% received iron supplements. Factors independently predictive of Hb included male gender (β=0.64, P2, P10 mg/day vs. none). Using a competing-risk regression model, Hb less than 9 in men and less than 8 in women, was associated with 5.25-fold higher risk of death-censored graft loss compared with no anemia (adjusted, P=0.005, CI: 1.7-16.7). Degree of anemia also remained significantly associated with risk of death (hazard ratio [HR]: 2.2, P

Original languageEnglish (US)
Pages (from-to)923-928
Number of pages6
JournalTransplantation
Volume93
Issue number9
DOIs
StatePublished - May 15 2012
Externally publishedYes

Fingerprint

Graft Survival
Kidney Transplantation
Anemia
Hematinics
Hemoglobins
Transplants
Iron
Immunosuppressive Agents
Bicarbonates
Allografts
Creatinine
Kidney
Serum

Keywords

  • Anemia
  • Graft survival
  • Kidney transplantation
  • Patient survival

ASJC Scopus subject areas

  • Transplantation

Cite this

Anemia after kidney transplantation; Its prevalence, risk factors, and independent association with graft and patient survival : A time-varying analysis. / Jones, Heather; Talwar, Manish; Nogueira, Joseph M.; Ugarte, Richard; Cangro, Charles; Rasheed, Hassaan; Klassen, David K.; Weir, Matthew R.; Haririan, Abdolreza.

In: Transplantation, Vol. 93, No. 9, 15.05.2012, p. 923-928.

Research output: Contribution to journalArticle

Jones, H, Talwar, M, Nogueira, JM, Ugarte, R, Cangro, C, Rasheed, H, Klassen, DK, Weir, MR & Haririan, A 2012, 'Anemia after kidney transplantation; Its prevalence, risk factors, and independent association with graft and patient survival: A time-varying analysis', Transplantation, vol. 93, no. 9, pp. 923-928. https://doi.org/10.1097/TP.0b013e31824b36fa
Jones, Heather ; Talwar, Manish ; Nogueira, Joseph M. ; Ugarte, Richard ; Cangro, Charles ; Rasheed, Hassaan ; Klassen, David K. ; Weir, Matthew R. ; Haririan, Abdolreza. / Anemia after kidney transplantation; Its prevalence, risk factors, and independent association with graft and patient survival : A time-varying analysis. In: Transplantation. 2012 ; Vol. 93, No. 9. pp. 923-928.
@article{9e03428b4a83479ab637324f3125b6ab,
title = "Anemia after kidney transplantation; Its prevalence, risk factors, and independent association with graft and patient survival: A time-varying analysis",
abstract = "Introduction: Posttransplant anemia and its association with transplant outcomes have not been properly studied. Methods: We examined 530 renal allograft recipients transplanted at our center and followed up for 31.0±14.1 months. Hemoglobin (Hb), serum bicarbonate, and creatinine; use of erythropoiesis-stimulating agent (ESA) and iron; and immunosuppressive regimen data were obtained at multiple time points during 24-month posttransplant. Results: The overall prevalence of anemia was 89.4{\%} at the time of transplant, dropping to 49.2{\%} at 1 year and 44.3{\%} at 2 years. ESA use decreased from 25.6{\%} at 1 month to 8.23{\%} at 24 months, only in 30.9{\%} to 51.2{\%} with severe anemia; 21.0{\%} to 29.2{\%} received iron supplements. Factors independently predictive of Hb included male gender (β=0.64, P2, P10 mg/day vs. none). Using a competing-risk regression model, Hb less than 9 in men and less than 8 in women, was associated with 5.25-fold higher risk of death-censored graft loss compared with no anemia (adjusted, P=0.005, CI: 1.7-16.7). Degree of anemia also remained significantly associated with risk of death (hazard ratio [HR]: 2.2, P",
keywords = "Anemia, Graft survival, Kidney transplantation, Patient survival",
author = "Heather Jones and Manish Talwar and Nogueira, {Joseph M.} and Richard Ugarte and Charles Cangro and Hassaan Rasheed and Klassen, {David K.} and Weir, {Matthew R.} and Abdolreza Haririan",
year = "2012",
month = "5",
day = "15",
doi = "10.1097/TP.0b013e31824b36fa",
language = "English (US)",
volume = "93",
pages = "923--928",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Anemia after kidney transplantation; Its prevalence, risk factors, and independent association with graft and patient survival

T2 - A time-varying analysis

AU - Jones, Heather

AU - Talwar, Manish

AU - Nogueira, Joseph M.

AU - Ugarte, Richard

AU - Cangro, Charles

AU - Rasheed, Hassaan

AU - Klassen, David K.

AU - Weir, Matthew R.

AU - Haririan, Abdolreza

PY - 2012/5/15

Y1 - 2012/5/15

N2 - Introduction: Posttransplant anemia and its association with transplant outcomes have not been properly studied. Methods: We examined 530 renal allograft recipients transplanted at our center and followed up for 31.0±14.1 months. Hemoglobin (Hb), serum bicarbonate, and creatinine; use of erythropoiesis-stimulating agent (ESA) and iron; and immunosuppressive regimen data were obtained at multiple time points during 24-month posttransplant. Results: The overall prevalence of anemia was 89.4% at the time of transplant, dropping to 49.2% at 1 year and 44.3% at 2 years. ESA use decreased from 25.6% at 1 month to 8.23% at 24 months, only in 30.9% to 51.2% with severe anemia; 21.0% to 29.2% received iron supplements. Factors independently predictive of Hb included male gender (β=0.64, P2, P10 mg/day vs. none). Using a competing-risk regression model, Hb less than 9 in men and less than 8 in women, was associated with 5.25-fold higher risk of death-censored graft loss compared with no anemia (adjusted, P=0.005, CI: 1.7-16.7). Degree of anemia also remained significantly associated with risk of death (hazard ratio [HR]: 2.2, P

AB - Introduction: Posttransplant anemia and its association with transplant outcomes have not been properly studied. Methods: We examined 530 renal allograft recipients transplanted at our center and followed up for 31.0±14.1 months. Hemoglobin (Hb), serum bicarbonate, and creatinine; use of erythropoiesis-stimulating agent (ESA) and iron; and immunosuppressive regimen data were obtained at multiple time points during 24-month posttransplant. Results: The overall prevalence of anemia was 89.4% at the time of transplant, dropping to 49.2% at 1 year and 44.3% at 2 years. ESA use decreased from 25.6% at 1 month to 8.23% at 24 months, only in 30.9% to 51.2% with severe anemia; 21.0% to 29.2% received iron supplements. Factors independently predictive of Hb included male gender (β=0.64, P2, P10 mg/day vs. none). Using a competing-risk regression model, Hb less than 9 in men and less than 8 in women, was associated with 5.25-fold higher risk of death-censored graft loss compared with no anemia (adjusted, P=0.005, CI: 1.7-16.7). Degree of anemia also remained significantly associated with risk of death (hazard ratio [HR]: 2.2, P

KW - Anemia

KW - Graft survival

KW - Kidney transplantation

KW - Patient survival

UR - http://www.scopus.com/inward/record.url?scp=84860731199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860731199&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e31824b36fa

DO - 10.1097/TP.0b013e31824b36fa

M3 - Article

VL - 93

SP - 923

EP - 928

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 9

ER -